Therapeutic observation and pharmacoeconomic analysis of two first-line chemo-therapy regimens in advanced NSCLC / 药学实践杂志

ABSTRACT

Objective To evaluate the cost-effectiveness of two chemotherapy regimens in NSCLC for the purpose of lower cost,higher quality medical care.Methods 56 patients with advanced NSCLC were divided into two groups from our hospital,group PP(pemtrexal+cisplatin,n=30)and group GP(gemcitabine+cisplatin,n=26),and analyzed by pharmaco-economic cost-effectiveness method,and retrospective analysis was also applied.Results Effective rates of two regimens were 46.67%,42.31%,no significant difference.But there was significant difference in the incidence rate of ADR between the two groups.The cost of chemotherapy regiments were 31 985.48 and 27 683.15 yuan.The average length of stay was 10.94 and 13·91 days.Compared to group GP,for each unit of efficacy,the cost in group PP were increased 986.77 yuan.Conclusion From the analysis of cost-effectiveness,group PP had higher chemotherapy costs,but better safety than group GP.